Daniele Vitone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniele Vitone has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Enza Lacivita
Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
2 shared publications - Marcello Leopoldo
Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
2 shared publications - Andrea Spinaci
Unit of Medicinal Chemistry, School of Pharmacy, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
1 shared publication - Angela Santo
Dipartimento di Farmacia—Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy
1 shared publication - Anna Pegoraro
Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy
1 shared publication - Beatrice Francucci
School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via Madonna delle Carceri snc, Camerino 62032, Italy
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 197, 119185
Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents
- 11 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 197, 119185
Open AccessSynthesis and characterization of new P2X7 receptor antagonists as antitumor agents
- Open Access
- 22 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 17
Beyond Radical Scavengers: Focus on NADPH Oxidases (NOX) Inhibitors as New Agents for Antioxidant Therapy in Alzheimer’s Disease
Over the past decade, oxidative stress and neuroinflammation have been increasingly recognized as part of the pathology of Alzheimer’s disease (AD). This observation has led to extensive efforts and attempts to apply antioxidant compounds as therapeutic agents for AD and other pathologies. However, most, if not all, of these attempts have failed in preclinical or clinical trials. A tentative explanation for this failure is radical scavengers’ intrinsic lack of specificity in either their mode or district of action. The lack of specificity has been thought by some to be a source of so-called “reductive stress”, another form of redox imbalance that might be just as toxic as oxidative stress. Thus, research interest is shifting from developing simple radical scavengers to designing and refining compounds targeting the overproduction of Reactive Oxygen Species (ROS) in specific pathological conditions. This can be achieved, for instance, by targeting the enzymes that are mainly responsible for their production, namely NADPH oxidases (NOX). In this review, we will discuss, from the point of view of medicinal chemistry, the main innovations in the development of NOX inhibitors and their potential employment for AD therapy. We will also discuss the experimental hurdles that slow down research in this field and possible solutions.
- 22 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 17
Open AccessBeyond Radical Scavengers: Focus on NADPH Oxidases (NOX) Inhibitors as New Agents for Antioxidant Therapy in Alzheimer’s Disease
Over the past decade, oxidative stress and neuroinflammation have been increasingly recognized as part of the pathology of Alzheimer’s disease (AD). This observation has led to extensive efforts and attempts to apply antioxidant compounds as therapeutic agents for AD and other pathologies. However, most, if not all, of these attempts have failed in preclinical or clinical trials. A tentative explanation for this failure is radical scavengers’ intrinsic lack of specificity in either their mode or district of action. The lack of specificity has been thought by some to be a source of so-called “reductive stress”, another form of redox imbalance that might be just as toxic as oxidative stress. Thus, research interest is shifting from developing simple radical scavengers to designing and refining compounds targeting the overproduction of Reactive Oxygen Species (ROS) in specific pathological conditions. This can be achieved, for instance, by targeting the enzymes that are mainly responsible for their production, namely NADPH oxidases (NOX). In this review, we will discuss, from the point of view of medicinal chemistry, the main innovations in the development of NOX inhibitors and their potential employment for AD therapy. We will also discuss the experimental hurdles that slow down research in this field and possible solutions.